subcutaneous semaglutide GLP-1s Wegovy® GLP-1 Semaglutide Injections -
Description
They require prescriptions
In 2024, the FDA approved Wegovy to reduce heart-related risks in people with cardiovascular disease who meet the criteria for overweight or obesity
Consistent weight loss at higher doses
Patients can verify medical provider licenses through state medical board websites, which maintain public license verification databases
